

Appendix 3Y – Change of Director’s Interest Notices

22 January 2026

Pursuant to ASX Listing Rule 3.19A.2, directors Andreas Fouras, Julian Sutton and John Livingston provide the attached Appendix 3Y disclosures.

These forms disclose the change in each director’s interest in 4DMedical Limited (ASX:4DX, “4DMedical”) as follows:

Andreas Fouras

In conjunction with the Placement announced on 15 January 2026, Dr Fouras exercised 1,850,914 options. To partially fund the options exercise cost, Velocimetry Consulting Pty Ltd (an entity associated with Dr Fouras) disposed of 263,157 shares. Following the options exercise process, Dr Fouras and related entities own 1,587,757 more shares than prior to the Placement.

Julian Sutton

In conjunction with the Placement announced on 15 January 2026, Mr Sutton exercised 4,266,666 options. To fully fund the option exercise cost and associated taxation liabilities, Mr Sutton disposed of 2,266,666 shares. Following the options exercise process, Mr Sutton owns 2,000,000 more shares than prior to the Placement.

John Livingston

John Livingston’s change in interest relates to the lapsing of 636,576 options. For the avoidance of doubt, Mr Livingston has not sold any shares.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical’s expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4DMedical Limited
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andreas Fouras
Date of last notice	18 December 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Ordinary shares held by Velocimetry Consulting Pty Ltd, being an entity in which Andreas has more than 20% voting power. Thus, Andreas is deemed to have the same relevant interest in 4DX shares as Velocimetry Consulting Pty Ltd pursuant to section 608(3) of the Corporations Act 2001.
Date of change	16 January 2026 and 21 January 2026
No. of securities held prior to change	Direct 11,277 Fully Paid Ordinary Shares 11,780,646 Unlisted Options Indirect 64,838,000 Fully Paid Ordinary Shares
Class	Options and Ordinary Shares
Number acquired	1,850,914 ordinary shares
Number disposed	1,850,914 unlisted options 263,157 ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1,850,914 unlisted options exercised at \$0.9508 per option 263,157 ordinary shares sold at \$3.80 per share
No. of securities held after change	Direct 1,862,191 Fully Paid Ordinary Shares 9,929,732 Unlisted Options Indirect 64,574,843 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unlisted options and sale of ordinary shares as disclosed in ASX announcement dated 15 January 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	There has been no change since the notice lodged on 1 September 2023.
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	12 January 2026

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4DMedical Limited
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Julian Bernard Kingsley Sutton
Date of last notice	18 December 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Vinegar Hill Partners Pty Ltd (an entity controlled by Julian Sutton)
Date of change	15 January 2026 and 21 January 2026
No. of securities held prior to change	Direct: 357,933 ordinary shares 4,266,666 unquoted options with exercise price of \$1.20 and expiry date of 15 March 2027 323,158 unquoted options with a nil exercise price and expiry date of 30 June 2030. Indirect: 183,014 ordinary shares
Class	Options and ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	4,266,666 ordinary shares
Number disposed	4,266,666 unquoted options 2,266,666 ordinary shares
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	4,266,666 unquoted options exercised at \$1.20 per option 2,666,666 ordinary shares sold at \$3.80 per share
No. of securities held after change	Direct: 2,357,933 ordinary shares 323,158 unquoted options with a nil exercise price and expiry date of 30 June 2030. Indirect: 183,014 ordinary shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of unlisted options and sale of ordinary shares as disclosed in ASX announcement dated 15 January 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	12 January 2026

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4DMedical Limited
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Livingston
Date of last notice	18 December 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ordinary shares in which the beneficial interest is held by John Livingston Pty Ltd, an entity controlled by John Livingston (registered holder: Colonial First State Inv Ltd <4916557 JOHN A/C>); and Ordinary shares in which the beneficial interest is held by JKEl Super Pty Ltd, an entity in which John Livingston has a voting power above 20% and thus is deemed by Section 608(3) of the Corporations Act 2001 to have the same relevant interest (registered holder: Colonial First State Inv Ltd <4916510 JKEl A/C>).
Date of change	17 January 2026

No. of securities held prior to change	<p>Direct 636,576 unquoted options exercisable at \$0.79 expiring 17 January 2026</p> <p>60,147 fully paid ordinary shares</p> <p>Indirect <u>Colonial First State Inv Ltd <4916557 JOHN A/C></u> <u>(beneficial holder John Livingston Pty Ltd)</u> 424,008 fully paid ordinary shares</p> <p>247,648 unquoted options with a nil exercise price and expiry date of 30 June 2030.</p> <p><u>Colonial First State Inv Ltd <4916510 JKEL A/C</u> <u>(beneficial holder: JKEL Super Pty Ltd)</u></p> <p>1,501,344 ordinary fully paid shares</p>
Class	Options exercisable at \$0.79 expiring 17 January 2026
Number acquired	Nil
Number disposed	636,576
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil
No. of securities held after change	<p>Direct 60,147 fully paid ordinary shares</p> <p>Indirect <u>Colonial First State Inv Ltd <4916557 JOHN A/C></u> <u>(beneficial holder John Livingston Pty Ltd)</u> 424,008 fully paid ordinary shares</p> <p>247,648 unquoted options with a nil exercise price and expiry date of 30 June 2030.</p> <p><u>Colonial First State Inv Ltd <4916510 JKEL A/C</u> <u>(beneficial holder: JKEL Super Pty Ltd)</u></p> <p>1,501,344 ordinary fully paid shares</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Expiry of options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.